Median Technologies Future Growth

Future criteria checks 2/6

Median Technologies is forecast to grow earnings and revenue by 2.9% and 20.3% per annum respectively while EPS is expected to grow by 4.3% per annum.

Key information

2.9%

Earnings growth rate

4.3%

EPS growth rate

Healthcare Services earnings growth	29.7%
Revenue growth rate	20.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	08 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:4ZG - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	36	-24	-24	-22	4
12/31/2025	28	-23	-23	-22	4
12/31/2024	24	-24	-22	-22	4
6/30/2024	22	-25	-20	-19	N/A
3/31/2024	23	-24	-21	-20	N/A
12/31/2023	23	-23	-22	-20	N/A
9/30/2023	23	-22	-20	-19	N/A
6/30/2023	23	-21	-19	-18	N/A
3/31/2023	23	-21	-18	-17	N/A
12/31/2022	24	-20	-17	-16	N/A
9/30/2022	24	-19	-16	-15	N/A
6/30/2022	23	-19	-15	-14	N/A
3/31/2022	22	-19	-13	-12	N/A
12/31/2021	21	-19	-11	-10	N/A
9/30/2021	19	-18	-10	-10	N/A
6/30/2021	18	-18	-10	-9	N/A
3/31/2021	16	-15	-8	-7	N/A
12/31/2020	14	-13	-6	-5	N/A
9/30/2020	12	-11	-4	-4	N/A
6/30/2020	11	-8	-3	-2	N/A
3/31/2020	10	-8	-4	-3	N/A
12/31/2019	9	-8	-5	-4	N/A
9/30/2019	8	-9	-8	-7	N/A
6/30/2019	7	-11	-11	-10	N/A
3/31/2019	7	-13	-13	-13	N/A
12/31/2018	6	-15	-16	-16	N/A
9/30/2018	7	-16	-17	-17	N/A
6/30/2018	7	-17	-18	-18	N/A
3/31/2018	7	-17	N/A	-16	N/A
12/31/2017	8	-17	N/A	-14	N/A
9/30/2017	8	-16	N/A	-12	N/A
6/30/2017	7	-14	N/A	-10	N/A
3/31/2017	7	-12	N/A	-9	N/A
12/31/2016	6	-9	N/A	-8	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-7	N/A	-5	N/A
3/31/2016	5	-6	N/A	-4	N/A
12/31/2015	4	-6	N/A	-4	N/A
9/30/2015	3	-5	N/A	-4	N/A
6/30/2015	2	-5	N/A	-5	N/A
3/31/2015	2	-5	N/A	-4	N/A
12/31/2014	2	-4	N/A	-3	N/A
9/30/2014	1	-4	N/A	N/A	N/A
6/30/2014	1	-4	N/A	N/A	N/A
3/31/2014	1	-4	N/A	N/A	N/A
12/31/2013	1	-4	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4ZG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4ZG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4ZG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4ZG's revenue (20.3% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 4ZG's revenue (20.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4ZG's Return on Equity is forecast to be high in 3 years time

Median Technologies Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast to breakeven in 2025

Recent updates

First half 2024 earnings released: €0.68 loss per share (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Median Technologies to Share Positive Pivotal Data for Eyonis LCS Diagnostic Software as Medical Device at the IASLC 2024 World Conference on Lung Cancer

Median Technologies Announces Pivotal Reality Study of Its Eyonis™? Lcs Lung Cancer Diagnostic Met All Primary and Secondary Endpoints

Median Technologies SA to Report First Half, 2024 Results on Oct 24, 2024

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: €1.25 loss per share (vs €1.28 loss in FY 2022)

New major risk - Share price stability

New minor risk - Share price stability

Median Technologies SA to Report Fiscal Year 2023 Results on Apr 25, 2024

Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA to Report First Half, 2023 Results on Oct 19, 2023

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: €1.28 loss per share (vs €1.25 loss in FY 2021)

Forecast to breakeven in 2025

Median Technologies SA to Report Fiscal Year 2022 Results on Apr 20, 2023

No independent directors

First half 2022 earnings released: €0.57 loss per share (vs €0.65 loss in 1H 2021)

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Median Technologies SA to Report Q3, 2022 Results on Oct 20, 2022

Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials

Median Technologies SA, Annual General Meeting, Jun 14, 2022

No independent directors

Full year 2021 earnings released: €1.25 loss per share (vs €1.06 loss in FY 2020)

Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies Announces New Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization

First half 2021 earnings released: €0.65 loss per share (vs €0.39 loss in 1H 2020)

Median Technologies SA announced that it has received €28.1 million in funding

Full year 2020 earnings released: €1.05 loss per share (vs €0.66 loss in FY 2019)

Median Technologies Appoints Thomas Bonnefont as Chief Operating and Commercial Officer

Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening

Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies